Weaver M L, Ashton J G, Zemel R
Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
Semin Surg Oncol. 1998 Mar;14(2):163-70. doi: 10.1002/(sici)1098-2388(199803)14:2<163::aid-ssu8>3.0.co;2-3.
One hundred fifty-eight procedures were performed on 136 patients with unresectable hepatic metastases using hepatic cryotherapy to ablate the tumors. The median age was 62 years. Patients included 90 males and 46 females. Fifty-eight patients had synchronous metastases, 55 had bilobar lesions, and 90 had precryo chemotherapy. Median preoperative carcinoembryonic antigen (CEA) level was 14.4 ng/dl. The numbers of lesions treated, frozen, and resected were two and one. Median survival of all patients was 30 months. Survival for 39 patients was 37 months. Patients with a CEA level > 100 ng/dl had a statistically worse survival rate than those with a level < 100 ng/dl (P < .001). Twenty patients underwent recryotherapy with median survival of 34 months. Recurrent disease developed in 78% of patients--82% of the patients developed liver recurrence. Complication rates were comparable to liver resection. Operative mortality was 3.7%. Hepatic cryotherapy is effective and safe in treating colorectal hepatic metastases under ultrasound guidance.
对136例无法切除的肝转移患者进行了158次肝冷冻消融手术以治疗肿瘤。中位年龄为62岁。患者包括90名男性和46名女性。58例患者有同步转移,55例有双叶病变,90例有冷冻前化疗。术前癌胚抗原(CEA)中位水平为14.4 ng/dl。治疗、冷冻和切除的病灶数量分别为2个和1个。所有患者的中位生存期为30个月。39例患者的生存期为37个月。CEA水平>100 ng/dl的患者生存率在统计学上低于水平<100 ng/dl的患者(P<.001)。20例患者接受了再次冷冻治疗,中位生存期为34个月。78%的患者出现复发疾病——82%的患者出现肝复发。并发症发生率与肝切除相当。手术死亡率为3.7%。超声引导下的肝冷冻消融术在治疗结直肠癌肝转移方面有效且安全。